[Retracted] Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C

Table 3

Distribution of patients with normal AHBV-DNA levels <500 copies/mL at different time periods.

Indicators (months)	Control group (n = 26)	Tenofovir group (n = 26)	Entecavir group (n = 26)
3	5 (20.08%)	13 (50.19%)#&	10 (40.15%)#
6	9 (33.47%)^∗	17 (66.92%)^∗#&	15 (56.88%)^∗#
12	10 (40.15%)^∗@	20 (76.96%)^∗@#&	17 (66.92%)^∗@#